Kidney Cancer Drugs Market to Reach USD 9.9 B by 2030 at ~6.9% CAGR

◉ Global Kidney Cancer Drugs Market to Grow from ~USD 6.1-6.9 Billion in 2024 to USD 8.1-9.9 Billion by 2030 at ~4.8-6.9% CAGR
According to multiple sources, the global Kidney Cancer Drugs market was valued at approximately USD 6.1 billion in 2024, rising from USD 6.51 B in 2023, and is projected to reach between USD 8.1 B (CAGR 4.8%)† and USD 9.9 B (CAGR 6.9%) by 2030

Download your sample copy of this report today! https://www.maximizemarketresearch.com/request-sample/66282/
◉ Market Overview & Growth Drivers
Growth is driven by rising incidence of renal cell carcinoma (RCC), lifestyle risk factors, aging populations, and improved diagnostics

RCC accounts for ~85-90% of all kidney cancers and contributes the majority of market revenue

Targeted therapies dominated (~53-57% share in 2023), while immunotherapy (e.g. checkpoint inhibitors) is expected to grow fastest at ~7.4% CAGR

For drug class, angiogenesis inhibitors held ~42-51% share in 2023; cytokine immunotherapy (IL‐2) is the fastest‐growing class at ~8.4% CAGR

Oral administration is dominant and expected to grow at ~5.6% CAGR due to convenience and home dosing trends

◉ Competitive Landscape
The market includes key players like Bayer AG, Bristol‐Myers Squibb, Novartis AG, Merck & Co., Astellas Pharma, Eisai, F. Hoffmann‐La Roche, GSK plc, Exelixis, and Helsinn Healthcare
Notable therapies include cabozantinib, everolimus, temsirolimus, avelumab, and nivolumab/Opdivo combinations.

Secure your sample copy of this report immediately!https://www.maximizemarketresearch.com/request-sample/66282/
◉ Regional Demand & High-Growth Regions
North America led the market in 2023 (~34-41% share; ~USD 2.2-2.3 B), projected to grow at ~5.3-5.5% CAGR to reach ~USD 3 B by 2032

Europe accounted for ~22.5% share in 2024 (~USD 1.29 B), growing at ~6.6% CAGR to reach ~USD 2.15 B by 2032

Asia-Pacific is the fastest-growing region, with ~25.5% share in 2024 (~USD 1.47 B), growing at ~7.1% CAGR to ~USD 2.57 B by 2032; China leads growth, followed by Japan and others

◉ COUNTRY-SPECIFIC INSIGHTS
Opportunity Growth in Vietnam
Vietnam is scaling cancer care infrastructure. As diagnosis rates improve, demand will rise for targeted and immunotherapies tailored for RCC patients.

Trends Growth in Thailand
Thailand's expanding oncology clinics and medical tourism demand both novel targeted agents and immunotherapy regimens, boosting drug uptake.

Consolidation Growth in Japan
Japanese healthcare providers increasingly partner with companies such as Bayer, Novartis, and Exelixis to bring VEGF‐TKIs and PD-1 agents into domestic RCC protocols.

Updation Innovation in South Korea
South Korea leads in integrating combination therapies (e.g., PD‐1 + VEGF inhibitors) and precision diagnostics into insurance-supported treatment pathways.

Benchmarking Opportunity in Singapore
Singapore's tertiary centers adopt novel RCC treatment combinations and participate in global clinical trials, serving as a regional benchmark in Asia.

Consolidation Trends in the United States
Merck's Keytruda saw ~20% revenue growth (to USD 6.95 B) and broadening kidney cancer approvals; Bristol-Myers Squibb advances Opdivo + Yervoy combinations, including injectable Opdivo Qvantig for kidney cancer use

Growth in China Trends
China is the largest contributor in Asia-Pacific, with fastest growth thanks to increasing RCC incidence, government reimbursement programs, and market access for international brands.

Opportunity & Compliance in Europe
Europe (especially Germany, UK, France) emphasizes early access programs and reimbursement frameworks, facilitating uptake of immunotherapy and combination regimens according to EMA approvals.

To learn more about the findings of this research, please check:https://www.maximizemarketresearch.com/market-report/global-kidney-cancer-drugs-market/66282/
◉ Kidney Cancer Drugs Market Segmentation:
by Therapeutic Class
Targeted Therapy
Immunotherapy
Chemotherapy

by Application
Drug Manufacturers
Hospitals and Clinics
Private and Government Research Institutes
Academic Institutes

◉ Mergers & Agreements & Regulatory Highlights
FDA approval in December 2024 of injectable Opdivo Qvantig simplifies administration for kidney cancer, expanding convenience and maintaining revenue as IV patents expire

Bayer's oncology division performance, including Kerendia and Nubeqa, lifted pharmaceutical revenue by ~4.1% for the quarter, indicating strong kidney drug uptake

Novel pipeline updates include BNT327 (BioNTech + Biotheus) in early-stage trials for PD-1/VEGF blockade in kidney cancer and promising combination therapies (e.g., zanzalintinib + nivolumab) highlighted in ASCO 2025

◉ Key Recent Developments
Increasing clinical trials and pipeline therapies-including novel neoantigen vaccines, ONC175 for tRCC, and personalized medicine platforms-are expected to expand treatment options through 2034

Combination therapies (e.g. VEGF‐TKI + immunotherapy, cytokine IL‐2 regimens) are reshaping treatment algorithms and improving outcomes in metastatic RCC

◉ Get Market Research Latest Trends
Global Patient Warming Systems Market https://www.maximizemarketresearch.com/market-report/global-patient-warming-systems-market/31514/

Global Antimicrobial Ingredients Market https://www.maximizemarketresearch.com/market-report/global-antimicrobial-ingredients-market/85303/

Therapeutic Respiratory Devices Market https://www.maximizemarketresearch.com/market-report/global-therapeutic-respiratory-devices-market/10111/

Electrophysiology Market https://www.maximizemarketresearch.com/market-report/global-electrophysiology-market/21498/

Follicular Lymphoma Treatment Market https://www.maximizemarketresearch.com/market-report/follicular-lymphoma-treatment-market/12594/

Global Capillary Electrophoresis Market https://www.maximizemarketresearch.com/market-report/global-capillary-electrophoresis-market/95834/

Global Protein Extracts from Single Cell Protein Sources Market https://www.maximizemarketresearch.com/market-report/global-protein-extracts-from-single-cell-protein-sources-market/87650/

Global Gastrointestinal Diseases Market https://www.maximizemarketresearch.com/market-report/gastrointestinal-diseases-market/304/

Global Kidney Stone Management Devices Market https://www.maximizemarketresearch.com/market-report/global-kidney-stone-management-devices-market/34959/

Global Orthopedic Surgical Power Tools Market https://www.maximizemarketresearch.com/market-report/global-orthopedic-surgical-power-tools-market/96822/

Global Clinical Trial Imaging Market https://www.maximizemarketresearch.com/market-report/global-clinical-trial-imaging-market/6603/

Diabetes Pen market https://www.maximizemarketresearch.com/market-report/global-diabetes-pen-market/53840/

Nutraceutical Excipients Market https://www.maximizemarketresearch.com/market-report/nutraceutical-excipients-market/187544/

◉Contact Maximize Market Research:

3rd Floor, Navale IT Park, Phase 2

Pune Banglore Highway, Narhe,

Pune, Maharashtra 411041, India

sales@maximizemarketresearch.com

+91 96071 95908, +91 9607365656

◉About Maximize Market Research:

Maximize Market Research is a multifaceted market research and consulting company with professionals from several industries. Some of the industries we cover include medical devices, pharmaceutical manufacturers, science and engineering, electronic components, industrial equipment, technology and communication, cars and automobiles, chemical products and substances, general merchandise, beverages, personal care, and automated systems. To mention a few, we provide market-verified industry estimations, technical trend analysis, crucial market research, strategic advice, competition analysis, production and demand analysis, and client impact studies.

This release was published on openPR.